Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Quanterix ( (QTRX) ).
On May 6, 2026, Quanterix reported first-quarter 2026 revenue of $36.4 million, up 20% year over year, with GAAP gross margin at 42.7%, adjusted gross margin at 50.9%, and an adjusted EBITDA loss of $9.8 million. The company ended the quarter with $102.6 million in cash and securities and updated its accounting to move shipping and handling costs for product sales into cost of revenue, while reiterating that it is progressing toward cash flow breakeven after extracting cost synergies from the Akoya acquisition.
Operationally, Quanterix advanced its fast-growing Alzheimer’s diagnostics business through collaborations with Tempus AI and Life Line Screening to broaden access to its LucentAD Complete and p-tau 217 blood tests, expanded oncology and neurology offerings via new assays, ADC cancer panels and participation in the ASAP Parkinson’s PD-BUILD program, and reaffirmed full-year 2026 guidance of $169 million to $174 million in revenue, targeted GAAP and adjusted gross margins, and an expectation of year-end cash near $100 million with no debt.
The most recent analyst rating on (QTRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Quanterix stock, see the QTRX Stock Forecast page.
Spark’s Take on QTRX Stock
According to Spark, TipRanks’ AI Analyst, QTRX is a Neutral.
The score is held down primarily by deteriorating profitability and accelerating cash burn, alongside a bearish technical setup. Offsetting factors include a low-debt balance sheet and management’s plan for cost synergies and cash-flow breakeven in H2 2026, but modest pro forma growth and organic demand weakness keep the outlook constrained.
To see Spark’s full report on QTRX stock, click here.
More about Quanterix
Quanterix Corporation, listed on Nasdaq under the ticker QTRX, is a global leader in ultra-sensitive biomarker detection technologies serving disease research, diagnostics, and drug development markets. Its proprietary Simoa platform measures biomarkers in blood and other fluids at far lower concentrations than traditional assays, and the 2025 acquisition of Akoya Biosciences added high-plex spatial tissue imaging, giving the combined company an integrated blood-and-tissue precision medicine offering.
Average Trading Volume: 797,415
Technical Sentiment Signal: Sell
Current Market Cap: $158.2M
Learn more about QTRX stock on TipRanks’ Stock Analysis page.